Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Altomoland is a pharmaceutical drug whose main active ingredient is Reduced Glutathione (GSH). GSH is a tripeptide containing a sulfhydryl (SH) group, naturally synthesized in human cells. It plays a vital role in activating the redox system, activating SH enzymes, and facilitating detoxification processes within the body. Altomoland participates in the tricarboxylic acid cycle and sugar metabolism, contributing to energy production and acting as a coenzyme. It promotes the metabolism of carbohydrates, fats, and proteins by activating SH enzymes and regulates cell membrane metabolic processes. Furthermore, it binds to various exogenous and endogenous toxic substances, aiding in their detoxification and excretion. Altomoland is used for liver protection, mitigating drug toxicity (including from chemotherapy and antituberculosis drugs), preventing and treating radiation damage, combating free radicals as an antioxidant, and enhancing overall immunity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Altomoland.